Graft versus host disease (GVHD) is a potentially life-threatening complication of allogenic hematopoietic stem-cell transplants (HSCTs). The systemic inflammatory reaction is triggered by donor T cells’ recognition of host cell antigens in nontarget tissue as foreign. Steroids have been the first-line therapy for decades for the prevention and treatment of GVHD. Interviewed experts cite a need for better treatments for steroid-refractory patients, as well as better first-line and prophylactic treatments for GVHD. Although development in this space has historically been slow, the pipeline for GVHD therapies is now robust. Here, we analyze GVHD patient populations, current therapies and medical practice, and the clinical and commercial opportunity for emerging therapies, including AbbVie/Janssen’s Imbruvica(ibrutinib), Mallinckrodt’s UVADEX(methoxsalen solution), and Incyte’s Jakafi (ruxolitinib).Leukotac (inolimomab) and Novartis’s Jakafi (ruxolitinib).


How large is the GVHD population, and how will it change through 2026? What percentage of the GVHD population receives drug treatment?

How is GVHD currently managed in the U.S. and EU5 countries? How well does the GVHD pipeline align with unmet clinical needs in the space?

What are the key drug targets in GVHD? Which emerging therapies do experts consider most promising? If approved, how would emerging therapies affect the management of GVHD? Which emerging drugs hold the greatest commercial potential?


Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.